BIO.B vs. ELAN: Bio-Rad Laboratories vs. Elanco Animal Health Stock Comparison
How do Bio-Rad Laboratories (BIO.B) and Elanco Animal Health (ELAN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Bio-Rad Laboratories (BIO.B) and Elanco Animal Health (ELAN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO.B is classified in Life Sciences Tools & Services while ELAN is classified in Pharmaceuticals.
| Profile Item | BIO.B | ELAN |
|---|---|---|
| Name | Bio-Rad Laboratories, Inc. Class B Common Stock | Elanco Animal Health Incorporated |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 10.49 billion USD | 13.39 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | September 21, 1999 | September 20, 2018 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIO.B | ELAN |
|---|---|---|
| Total Return (1Y) | 27.69% | 21.78% |
| Total Return (3Y, Annualized) | 9.13% | 36.41% |
| Total Return (5Y, Annualized) | -12.33% | -4.11% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Elanco Animal Health (ELAN) trades around 5.33M shares per day on average, while Bio-Rad Laboratories (BIO.B) sees only 11 — a volume gap that can matter for position sizing, exit liquidity, and order execution.
| Metric | BIO.B | ELAN |
|---|---|---|
| Volatility (1Y, Annualized) | 30.96% | 43.35% |
| Beta (5Y) | 1.00 | 1.70 |
| Max Drawdown (5Y) | -70.74% | -75.02% |
| Avg. Volume (3M) | 11 | 5.33M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIO.B | ELAN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 0.40 |
| Sortino Ratio (1Y) | 1.10 | 0.58 |
Profitability
ROE (TTM)
Elanco Animal Health (ELAN) reports a negative ROE of -2.20%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Bio-Rad Laboratories (BIO.B) reports 14.27%, ranking against industry peers normally.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO.B
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-2.20%
- Max
- 109.18%
- Q3
- 6.23%
- ELAN
- -2.20%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile Bio-Rad Laboratories (BIO.B) reports 39.45%, ranking against industry peers normally.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO.B
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-2.86%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- ELAN
- -2.86%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Bio-Rad Laboratories (BIO.B) at 9.46% and Elanco Animal Health (ELAN) at 7.71% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.46%
- Max
- 83.12%
- Q3
- 14.77%
- BIO.B
- 9.46%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.71%
- Max
- 83.12%
- Q3
- 14.77%
- ELAN
- 7.71%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIO.B | ELAN |
|---|---|---|
| ROE (TTM) | 14.27% | -2.20% |
| ROA (TTM) | 1.50% | 1.85% |
| Net Margin (TTM) | 39.45% | -2.86% |
| Operating Margin (TTM) | 9.46% | 7.71% |
| Gross Margin (TTM) | 52.19% | 56.18% |
Growth
Revenue Growth
Both Bio-Rad Laboratories (BIO.B) at 0.65% and Elanco Animal Health (ELAN) at 6.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Elanco Animal Health (ELAN) reports EPS growth of -169.12%, ranked against its industry; Bio-Rad Laboratories (BIO.B) has no EPS growth figure this period.
Growth Metrics
| Metric | BIO.B | ELAN |
|---|---|---|
| Revenue Growth (YoY) | 0.65% | 6.22% |
| Revenue Growth (3Y CAGR) | -2.68% | 2.25% |
| EPS Growth (YoY) | -- | -169.12% |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Bio-Rad Laboratories (BIO.B) at 3.18 keeps current ratio within its industry’s typical mid-range, while Elanco Animal Health (ELAN) at 2.09 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ELAN.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO.B
- 3.18
- Q1
- 2.47
- Min
- 0.10
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.09
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ELAN
- 2.09
- Min
- 0.10
Debt / Equity (MRQ)
Both Bio-Rad Laboratories (BIO.B) at 0.18 and Elanco Animal Health (ELAN) at 0.61 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO.B
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.61
- Max
- 1.42
- Q3
- 0.65
- ELAN
- 0.61
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIO.B | ELAN |
|---|---|---|
| Current Ratio (MRQ) | 3.18 | 2.09 |
| Debt / Equity (MRQ) | 0.18 | 0.61 |
| Net Debt / EBITDA | -0.73 | 3.33 |
Dividends
Dividend Yield (TTM)
Neither Bio-Rad Laboratories (BIO.B) nor Elanco Animal Health (ELAN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO.B
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Bio-Rad Laboratories (BIO.B) nor Elanco Animal Health (ELAN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO.B
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIO.B | ELAN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Bio-Rad Laboratories (BIO.B) trades at 10.36 times trailing earnings, ranked against its peers, while Elanco Animal Health (ELAN) has no P/E ratio this period.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.36
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO.B
- 10.36
- Min
- 0.07
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ELAN
- --
P/S Ratio (TTM)
Elanco Animal Health (ELAN) at 2.60 sits in the cheaper P/S ratio quartile while Bio-Rad Laboratories (BIO.B) at 4.05 prices around its industry’s middle — ELAN costs less per dollar of sales, though read it alongside growth and margins.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.05
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO.B
- 4.05
- Q1
- 3.01
- Min
- 0.01
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.60
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ELAN
- 2.60
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO.B) at 1.38 sits in the lower P/B ratio quartile against book while Elanco Animal Health (ELAN) at 2.02 is valued near its industry’s middle — BIO.B is cheaper on assets, though weigh it against ROE and asset quality.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.38
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO.B
- 1.38
- Min
- -5.59
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.02
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- ELAN
- 2.02
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BIO.B | ELAN |
|---|---|---|
| P/E Ratio (TTM) | 10.36 | -- |
| P/S Ratio (TTM) | 4.05 | 2.60 |
| P/B Ratio (MRQ) | 1.38 | 2.02 |
| Free Cash Flow Yield (TTM) | 2.59% | 5.12% |